<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Onco Targets Ther</journal-id><journal-id journal-id-type="iso-abbrev">Onco Targets Ther</journal-id><journal-id journal-id-type="publisher-id">ott</journal-id><journal-title-group><journal-title>OncoTargets and Therapy</journal-title></journal-title-group><issn pub-type="epub">1178-6930</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9440701</article-id><article-id pub-id-type="publisher-id">376647</article-id><article-id pub-id-type="doi">10.2147/OTT.S376647</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Tumor Heterogeneity and Drug Resistance Mutations Using ctDNA in Metastatic <italic toggle="yes">EGFR</italic> Mutation-Positive Lung Adenocarcinoma: A Case Report</article-title><alt-title alt-title-type="running-authors">Sun et al</alt-title><alt-title alt-title-type="running-title">Sun et al</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Sun</surname><given-names>Jinghua</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Sun</surname><given-names>Ge</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>KeMou</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Lingling</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Qu</surname><given-names>XiaoNa</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Ye</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Evenki</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Peng</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Tingting</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yang</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>HongMei</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><aff id="aff0001"><label>1</label><institution>The Second Affiliated Hospital of Dalian Medical University</institution>, <addr-line>Dalian</addr-line>, <country>People&#x02019;s Republic of China</country></aff><aff id="aff0002"><label>2</label><institution>Nanjing Geneseeq Technology Inc</institution>., <addr-line>Nanjing</addr-line>, <country>People&#x02019;s Republic of China</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Yang Zhang; HongMei He, <institution>The Second Affiliated Hospital of Dalian Medical University, Dalian</institution>, <addr-line>No. 467, Zhongshan Road, Shahekou District</addr-line>, <addr-line>Dalian</addr-line>, <country>People&#x02019;s Republic of China</country>, Email zydley@163.com; hongmeihe1976@163.com</corresp><fn id="ft0001"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>15</volume><fpage>919</fpage><lpage>923</lpage><history><date date-type="received"><day>29</day><month>5</month><year>2022</year></date><date date-type="accepted"><day>01</day><month>8</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 Sun et al.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Sun et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><title>Abstract</title><p>For advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (<italic toggle="yes">EGFR</italic>) mutations, <italic toggle="yes">EGFR</italic> tyrosine kinase inhibitors (TKIs) have been approved as the standard therapy and shown clinical benefits. However, the emergence of drug resistance is inevitable. Tumor heterogeneity was often observed by imaging method to evaluate the progression of primary and metastatic lesions. Tissue biopsy was also unlikely to accurately capture the complete genomic landscape from a single tissue sample. Recently, genomic characterization of circulating tumor DNA (ctDNA) offer an opportunity to reveal the clonal dynamics throughout the course of a patient&#x02019;s illness and provide comprehensive genomic landscape of tumors to assess tumor heterogeneity. Here, we reported a lung adenocarcinoma (LADC) with <italic toggle="yes">EGFR</italic> mutations who was treated with sequential <italic toggle="yes">EGFR</italic> TKIs. The CT image of the patient&#x02019;s different lesions suggested that dynamic change of tumor heterogeneity had occurred. Targeted next-generation sequencing (NGS) analysis of ctDNA revealed dynamic changes of mutational profiles between the primary and metastatic tumors to discover tumor evolution to guide treatment decision-making.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>tumor heterogeneity</kwd><kwd>circulating tumor DNA</kwd><kwd>ctDNA</kwd><kwd>resistance mutation</kwd><kwd>next-generation sequencing</kwd><kwd>NGS</kwd></kwd-group><funding-group><award-group><funding-source>
<institution-wrap><institution>This research did not receive any specific funding</institution></institution-wrap>
</funding-source></award-group><funding-statement>This research did not receive any specific funding.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="2"/><ref-count count="15"/><page-count count="5"/></counts></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>In Asian non-small cell lung cancer (NSCLC) patients, somatic activating mutations in the epidermal growth factor receptor (<italic toggle="yes">EGFR</italic>) such as point mutation L858R within exon 21 and short in-frame deletions within exon 19 are the most common oncogenic driver mutation.<xref rid="cit0001" ref-type="bibr">1</xref> With the development of targeted therapy and next-generation sequencing (NGS) technology, the therapeutic strategies for lung cancer have evolved into a new era of genomics-guided precision medicine. These <italic toggle="yes">EGFR</italic>-targeted tyrosine kinase inhibitors (TKIs) have shown improved tumor response and progression-free survival (PFS) outcome in <italic toggle="yes">EGFR</italic>-mutated NSCLC.<xref rid="cit0002" ref-type="bibr">2</xref> Although <italic toggle="yes">EGFR</italic> T790M mutation have been confirmed as first- and second-generation <italic toggle="yes">EGFR</italic>-TKIs resistance mutations, a third-generation <italic toggle="yes">EGFR</italic>-TKI of osimertinib has shown efficacy in counteracting the growth of <italic toggle="yes">EGFR</italic> T790M mutant tumors.<xref rid="cit0003" ref-type="bibr">3</xref> Although osimertinib has demonstrated high clinical efficacy, developing resistance is also inevitable.</p><p>The biggest hurdle for the successful treatment of cancer is the tumor heterogeneity, which can take different forms of intratumor, intermetastatic or intrametastatic heterogeneity within an individual patient.<xref rid="cit0004" ref-type="bibr">4</xref> Computed tomography (CT) remains the initial imaging method for clinical staging of lung cancer, evaluating the change of primary and metastatic lesions. Recently, gene sequencing of circulating tumor DNA (ctDNA) from a liquid biopsy or blood sample can provide comprehensive genetic information of all cancerous lesions (primary and metastases), which overcomes spatial and temporal heterogeneity of a single-tumor biopsy sample, as well as facilitates dynamic tracking of genomic evolution for formatting a treatment strategy.<xref rid="cit0005" ref-type="bibr">5</xref></p><p>We herein report a case of lung adenocarcinoma (LADC) with <italic toggle="yes">EGFR</italic> mutations, whose different tumor lesions exhibited different response to the <italic toggle="yes">EGFR</italic>-TKIs. The NGS analysis of ctDNA revealed dynamic changes of mutational profiles between the primary and metastatic tumors.</p></sec><sec id="s0002"><title>Case Report</title><p>A 44-year-old female was diagnosed with stage IV LADC (cT2bN2M1c) in the right lung center with lymph nodes metastases in February 2017. Positron emission tomography-computed tomography (PET-CT) scan indicated a 14&#x000d7;9 mm density mass in the upper lobe of right lung and a 23&#x000d7;7 mm density mass in the right hilum, respectively (<xref rid="f0001" ref-type="fig">Figure 1</xref>). Immunohistochemistry (IHC) staining of tumor biopsy showed positive for LADC markers thyroid transcription factor-1 (TTF-1) and Napsin-A, but negative for lung squamous cell carcinoma (LSCC) markers P40 and P63. NGS demonstrated <italic toggle="yes">EGFR</italic> L858R with a mutation allelic frequency (MAF) of 0.5%, in plasma and 19.7% in tumor tissue of the upper lobe of right lung, and <italic toggle="yes">TP53</italic> R282W with a MAF of 29.9% in plasma and 43.5% in tumor tissue of the upper lobe of right lung (<xref rid="t0001" ref-type="table">Table 1</xref>). Then, the patient was treated with gefitinib (250 mg QD) in April 2017, which is a first-generation <italic toggle="yes">EGFR</italic>-TKI. In November 2017, the lesions in the upper lobe of right lung deceased to 14&#x000d7;4 mm, the size of the right hilum lesion increased to 27&#x000d7;14 mm and a new 11&#x000d7;8 mm density mass in the mediastinal lymph nodes occurred (<xref rid="f0001" ref-type="fig">Figure 1</xref>). The patient reached a progression-free survival (PFS) of 7 months. In order to find more efficient therapeutic strategy, targeted NGS was applied in the plasma sample and it revealed <italic toggle="yes">EGFR</italic> T790M (MAF = 1.2%), <italic toggle="yes">EGFR</italic> L858R (MAF = 2%) and <italic toggle="yes">TP53</italic> R282W (MAF = 31.7%) (<xref rid="t0001" ref-type="table">Table 1</xref>). The patient was then switched to osimertinib, a third-generation <italic toggle="yes">EGFR</italic>-TKI (80 mg QD) that is selective for T790M resistance mutations,<xref rid="cit0006" ref-type="bibr">6</xref> and achieved an initial partial response (PR) with sustained response ongoing for 7 months. In July 2018, the size of the upper lobe of right lung and right hilum lesion increased to 18&#x000d7;13 mm and 65&#x000d7;36 mm, respectively, which indicated a PD (<xref rid="f0001" ref-type="fig">Figure 1</xref>). However, the size of lesions in the mediastinal lymph nodes decreased to 8&#x000d7;4 mm. The follow-up genomic testing indicated <italic toggle="yes">EGFR</italic> L718Q (MAF =1.6%), <italic toggle="yes">EGFR</italic> T790M (MAF = 1.0%), <italic toggle="yes">EGFR</italic> L858R (MAF = 5.8%) and <italic toggle="yes">TP53</italic> R282W (MAF = 42.1%) in the plasma sample (<xref rid="t0001" ref-type="table">Table 1</xref>). Due to the occurrence of <italic toggle="yes">EGFR</italic> L718Q, as a mechanism of acquired resistance to osimertinib, the therapy was switched to GC treatment (gemcitabine 1000 mg/m<sup>2</sup> and carboplatin AUC 5 on Day 1, and gemcitabine 1000 mg/m<sup>2</sup> on Day 8 of a 21-day cycle). However, the size of the upper lobe of right lung, mediastinal lymph nodes and right hilum lesion increased to 18&#x000d7;17 mm, 15&#x000d7;12 mm and 110&#x000d7;80 mm, respectively, which indicated a PD (<xref rid="f0001" ref-type="fig">Figure 1</xref>) and targeted NGS revealed <italic toggle="yes">EGFR</italic> L718Q (MAF =1.6%), <italic toggle="yes">EGFR</italic> T790M (MAF = 0.8%), <italic toggle="yes">EGFR</italic> L858R (MAF = 3.4%) and <italic toggle="yes">TP53</italic> R282W (MAF = 37.7%) in the plasma sample in December 2018 (<xref rid="t0001" ref-type="table">Table 1</xref>). Unfortunately, the patient died in January 2019.<table-wrap position="float" id="t0001"><label>Table 1</label><caption><p>Genetic Alterations by Targeted NGS in the Primary Tumor of the Upper Lobe of Right Lung and Serial Plasma ctDNA</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" colspan="1">Gene</th><th rowspan="3" colspan="1">Alteration</th><th rowspan="2" colspan="2">Baseline</th><th colspan="3" rowspan="1">Post-Treatment</th></tr><tr><th rowspan="1" colspan="1">Gefitinib</th><th rowspan="1" colspan="1">Osimertinib</th><th rowspan="1" colspan="1">Chemotherapy</th></tr><tr><th rowspan="1" colspan="1">FFPE</th><th rowspan="1" colspan="1">Plasma</th><th rowspan="1" colspan="1">Plasma</th><th rowspan="1" colspan="1">Plasma</th><th rowspan="1" colspan="1">Plasma</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><italic toggle="yes">TP53</italic></td><td rowspan="1" colspan="1">R282W</td><td rowspan="1" colspan="1">43.5%</td><td rowspan="1" colspan="1">29.9%</td><td rowspan="1" colspan="1">31.7%</td><td rowspan="1" colspan="1">42.1%</td><td rowspan="1" colspan="1">37.7%</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">EGFR</italic></td><td rowspan="1" colspan="1">L858R</td><td rowspan="1" colspan="1">19.7%</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">2%</td><td rowspan="1" colspan="1">5.8%</td><td rowspan="1" colspan="1">3.4%</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">EGFR</italic></td><td rowspan="1" colspan="1">T790M</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">1.2%</td><td rowspan="1" colspan="1">1.0%</td><td rowspan="1" colspan="1">0.8%</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">EGFR</italic></td><td rowspan="1" colspan="1">L718Q</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">1.6%</td><td rowspan="1" colspan="1">1.6%</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Abbreviations</bold>: FFPE, formalin-fixed; paraffin-embedded; &#x0201c;-&#x0201d;, not detected; GC, gemcitabine and carboplatin; ctDNA, circulating tumor DNA.</p></fn></table-wrap-foot></table-wrap>
<fig position="float" id="f0001" fig-type="figure"><label>Figure 1</label><caption><p>Treatment history and CT images of three lesions during the treatments. (<bold>A</bold>) Timeline of treatments and timepoints of NGS sample collections are shown. CT images of (<bold>B</bold>) the upper lobe of right lung, (<bold>C</bold>) the right hilum lesion, and (<bold>D</bold>) the mediastinal lymph nodes during the treatments. Tumors are indicated by red arrows.</p></caption><graphic xlink:href="OTT-15-919-g0001" content-type="print-only" position="float"/><attrib><bold>Abbreviations</bold>: NGS, next-generation sequencing; PFS, progression-free survival; mo, months.</attrib></fig></p></sec><sec id="s0003"><title>Discussion</title><p>Tumor heterogeneity has been one of the major huddles for the successful treatment of cancer, which is largely attribute to differences in somatic mutations in the tumor.<xref rid="cit0007" ref-type="bibr">7</xref> Heterogeneity is also often seen in an individual patient and can take different forms including intratumor, intermetastatic or intrametastatic heterogeneity.<xref rid="cit0004" ref-type="bibr">4</xref> Heterogeneity between different malignant lesions is common in patients with advanced metastatic cancer.<xref rid="cit0008" ref-type="bibr">8</xref> In this case, the response to the treatments differed in different lesions suggested intermetastatic heterogeneity. Multiple factors may lead to tumor heterogeneity and tumor evolution, including mutational burden, copy number variation and genome doubling.<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0010" ref-type="bibr">10</xref> Some therapies can also contribute to genomic diversity. In this study, the patient was diagnosed with LADC with <italic toggle="yes">EGFR</italic> L858R. Sequential administration of <italic toggle="yes">EGFR</italic> TKIs (gefitinib and osimertinib) was performed. For acquired mutations detection, such as <italic toggle="yes">EGFR</italic> T790M, the usefulness of liquid biopsy has already been reported and used in clinical practice.<xref rid="cit0011" ref-type="bibr">11</xref> However, such treatment also accelerated the accumulation of <italic toggle="yes">EGFR</italic>-resistance mutations, including the occurrence of <italic toggle="yes">EGFR</italic>-resistance mutations, such as <italic toggle="yes">EGFR</italic> T790M and <italic toggle="yes">EGFR</italic> L718Q. The emergence of acquired drug resistance limited the duration of tumor response and gave rise to tumor progress as new metastatic lesions or as proliferation of previous tumor lesions, which could be detected by clinical imaging studied. Genomic instability is the most prominent factor that drive tumor heterogeneity since different cells acquire unique mutations that lead to genetically distinct subpopulation.<xref rid="cit0012" ref-type="bibr">12</xref> Tumor heterogeneity is also acts as a potentiator of acquired resistance regardless of the therapy.<xref rid="cit0013" ref-type="bibr">13</xref></p><p>The patient&#x02019;s tumor sample was insufficient for genetic testing for the dynamic monitoring. Moreover, molecular characterization of a sample from a primary or metastatic lesion, which often obtained from a needle biopsy or surgical excision, was unlikely to accurately capture the complete genomic landscape. The analysis of ctDNA has been used as a biomarker to assess clonal dynamic progression throughout the course of a patient&#x02019;s treatment, identify drivers of acquired resistance and assess tumor heterogeneity.<xref rid="cit0014" ref-type="bibr">14</xref>,<xref rid="cit0015" ref-type="bibr">15</xref> The CT image of the patient&#x02019;s different lesions suggested that dynamic change of tumor heterogeneity had occurred. Genomic characterization of ctDNA revealed the mutational pattern to help recognize whole genetic alterations occurring in the whole body, which had a potential to demonstrate this heterogeneity (<xref rid="f0002" ref-type="fig">Figure 2</xref>), but not in all tumors. The genetic testing based on ctDNA may also offer an opportunity to predict the efficacy of therapeutic approach to improve clinical outcomes.<fig position="float" id="f0002" fig-type="figure"><label>Figure 2</label><caption><p>Development of tumor heterogeneity and changes in the allele frequencies (AFs) of <italic toggle="yes">TP53</italic> and <italic toggle="yes">EGFR</italic> mutations. (<bold>A</bold>) Models of clonal evolution and (<bold>B</bold>) the AFs of <italic toggle="yes">TP53</italic> and <italic toggle="yes">EGFR</italic> mutations are shown through the plasma ctDNA sequencing.</p></caption><graphic xlink:href="OTT-15-919-g0002" content-type="print-only" position="float"/></fig></p><p>There are still several limitations of our study which should be further studied in the future. We did not have tumor samples for the dynamic monitoring to validate the tumor heterogeneity. Additionally, further research is warranted to study more effective therapy.</p></sec><sec id="s0004"><title>Conclusion</title><p>Our report presented LADC patient with <italic toggle="yes">EGFR</italic> L858R who was treated with sequential <italic toggle="yes">EGFR</italic>-TKIs and developed resistance mutations, which were detected by dynamic NGS monitoring. The CT image of different lesion during the course of treatment revealed tumor heterogeneity. We highlight the importance of dynamic monitoring of ctDNA using NGS to assess tumor heterogeneity and guide treatment decision-making.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank the patient for providing written informed consent for publication.</p></ack><sec id="s0005"><title>Date Availability</title><p>All data sets generated for this study are included in the manuscript.</p></sec><sec id="s0006"><title>Ethics Statement</title><p>This study involving human participants were reviewed and approved by Ethics Committee of the Second Affiliated Hospital of Dalian Medical University. The patient provided written informed consent to participate in this study.</p></sec><sec id="s0007"><title>Author Contributions</title><p>All authors performed data analysis, drafted or revised the manuscript, agreed on the journal to which the article was submitted, approved the final version of the manuscript, and agreed to be accountable for all aspects of the work.</p></sec><sec sec-type="COI-statement" id="s0008"><title>Disclosure</title><p>Authors Evenki Pan, Peng Yang, and Tingting Wu are employed by Nanjing Geneseeq Technology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Midha</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dearden</surname>
<given-names>S</given-names></string-name>, <string-name><surname>McCormack</surname>
<given-names>R</given-names></string-name>. <article-title>EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)</article-title>. <source><italic toggle="yes">Am J Cancer Res</italic></source>. <year>2015</year>;<volume>5</volume>(<issue>9</issue>):<fpage>2892</fpage>&#x02013;<lpage>2911</lpage>.<pub-id pub-id-type="pmid">26609494</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Siegel</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Miller</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>Fuchs</surname>
<given-names>HE</given-names></string-name>, <string-name><surname>Jemal</surname>
<given-names>A</given-names></string-name>. <article-title>Cancer statistics, 2021</article-title>. <source><italic toggle="yes">CA Cancer J Clin</italic></source>. <year>2021</year>;<volume>71</volume>(<issue>1</issue>):<fpage>7</fpage>&#x02013;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21654</pub-id><pub-id pub-id-type="pmid">33433946</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Gristina</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Malapelle</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Galvano</surname>
<given-names>A</given-names></string-name>, et al. <article-title>The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: a systematic review and critical appraisal</article-title>. <source><italic toggle="yes">Cancer Treat Rev</italic></source>. <year>2020</year>;<volume>85</volume>:<fpage>101994</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ctrv.2020.101994</pub-id><pub-id pub-id-type="pmid">32113081</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>El-Sayes</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Vito</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mossman</surname>
<given-names>K</given-names></string-name>. <article-title>Tumor heterogeneity: a great barrier in the age of cancer immunotherapy</article-title>. <source><italic toggle="yes">Cancers</italic></source>. <year>2021</year>;<volume>13</volume>(<issue>4</issue>):<fpage>806</fpage>. doi:<pub-id pub-id-type="doi">10.3390/cancers13040806</pub-id><pub-id pub-id-type="pmid">33671881</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Sorber</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zwaenepoel</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Deschoolmeester</surname>
<given-names>V</given-names></string-name>, et al. <article-title>Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients</article-title>. <source><italic toggle="yes">Lung Cancer</italic></source>. <year>2017</year>;<volume>107</volume>:<fpage>100</fpage>&#x02013;<lpage>107</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.lungcan.2016.04.026</pub-id><pub-id pub-id-type="pmid">27180141</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Cross</surname>
<given-names>DAE</given-names></string-name>, <string-name><surname>Ashton</surname>
<given-names>SE</given-names></string-name>, <string-name><surname>Ghiorghiu</surname>
<given-names>S</given-names></string-name>, et al. <article-title>AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</article-title>. <source><italic toggle="yes">Cancer Discov</italic></source>. <year>2014</year>;<volume>4</volume>(<issue>9</issue>):<fpage>1046</fpage>&#x02013;<lpage>1061</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0337</pub-id><pub-id pub-id-type="pmid">24893891</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Lim</surname>
<given-names>Z-F</given-names></string-name>, <string-name><surname>Ma</surname>
<given-names>PC</given-names></string-name>. <article-title>Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy</article-title>. <source><italic toggle="yes">J Hematol Oncol</italic></source>. <year>2019</year>;<volume>12</volume>(<issue>1</issue>):<fpage>134</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13045-019-0818-2</pub-id><pub-id pub-id-type="pmid">31815659</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Fisher</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Pusztai</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Swanton</surname>
<given-names>C</given-names></string-name>. <article-title>Cancer heterogeneity: implications for targeted therapeutics</article-title>. <source><italic toggle="yes">Br J Cancer</italic></source>. <year>2013</year>;<volume>108</volume>(<issue>3</issue>):<fpage>479</fpage>&#x02013;<lpage>485</lpage>. doi:<pub-id pub-id-type="doi">10.1038/bjc.2012.581</pub-id><pub-id pub-id-type="pmid">23299535</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Jamal-Hanjani</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wilson</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>McGranahan</surname>
<given-names>N</given-names></string-name>, et al. <article-title>Tracking the evolution of non&#x02013;small-cell lung cancer</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2017</year>;<volume>376</volume>(<issue>22</issue>):<fpage>2109</fpage>&#x02013;<lpage>2121</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1616288</pub-id><pub-id pub-id-type="pmid">28445112</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Genomic heterogeneity of multiple synchronous lung cancer</article-title>. <source><italic toggle="yes">Nat Commun</italic></source>. <year>2016</year>;<volume>7</volume>(<issue>1</issue>):<fpage>13200</fpage>. doi:<pub-id pub-id-type="doi">10.1038/ncomms13200</pub-id><pub-id pub-id-type="pmid">27767028</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Del Re</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Crucitta</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gianfilippo</surname>
<given-names>G</given-names></string-name>, et al. <article-title>Understanding the mechanisms of resistance in EGFR-positive NSCLC: from tissue to liquid biopsy to guide treatment strategy</article-title>. <source><italic toggle="yes">Int J Mol Sci</italic></source>. <year>2019</year>;<volume>20</volume>(<issue>16</issue>):<fpage>3951</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms20163951</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Hanahan</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Weinberg Robert</surname>
<given-names>A</given-names></string-name>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source><italic toggle="yes">Cell</italic></source>. <year>2011</year>;<volume>144</volume>(<issue>5</issue>):<fpage>646</fpage>&#x02013;<lpage>674</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Ram&#x000f3;n y Cajal</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ses&#x000e9;</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Capdevila</surname>
<given-names>C</given-names></string-name>, et al. <article-title>Clinical implications of intratumor heterogeneity: challenges and opportunities</article-title>. <source><italic toggle="yes">J Mol Med</italic></source>. <year>2020</year>;<volume>98</volume>(<issue>2</issue>):<fpage>161</fpage>&#x02013;<lpage>177</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00109-020-01874-2</pub-id><pub-id pub-id-type="pmid">31970428</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Ma</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Guan</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yi</surname>
<given-names>Z</given-names></string-name>, et al. <article-title>Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer</article-title>. <source><italic toggle="yes">Int J Cancer</italic></source>. <year>2020</year>;<volume>146</volume>(<issue>5</issue>):<fpage>1359</fpage>&#x02013;<lpage>1368</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.32536</pub-id><pub-id pub-id-type="pmid">31241775</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Nakada</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Nakagomi</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hirotsu</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>A study of tumor heterogeneity in a case with breast cancer</article-title>. <source><italic toggle="yes">Breast Cancer</italic></source>. <year>2017</year>;<volume>24</volume>(<issue>3</issue>):<fpage>483</fpage>&#x02013;<lpage>489</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12282-016-0733-0</pub-id><pub-id pub-id-type="pmid">27687626</pub-id></mixed-citation></ref></ref-list></back></article>
